Novelwise Pharmaceutical Corporation Press Releases - EIN Presswire

Published on September 23, 2026 - 08:08 GMT

NovelWise Announces QuantHealth Collaboration to Advance AI-Enabled Oncology Development

Collaboration brings together oncology expertise and artificial intelligence to support evidence-informed development decisions SAN DIEGO, CA, UNITED STATES, September 23, 2026 /⁨EINPresswire.com⁩/ -- NovelWise Pharmaceutical Corporation USA (“NovelWise …

Distribution channels: ...

Published on December 15, 2025 - 06:21 GMT

NovelWise Pharma Announces First Patient Dosed in Phase I/II Trial of NBM-BMX for Metastatic Uveal Melanoma

NovelWise announces first patient dosed in its Phase I/II trial of NBM-BMX for metastatic uveal melanoma, following FDA Fast Track and Orphan Drug designations SAN DIEGO, CA, UNITED STATES, December 15, 2025 /⁨EINPresswire.com⁩/ -- NovelWise …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 24, 2025 - 06:40 GMT

FDA Grants Orphan Drug Designation to NovelWise’s NBM-BMX for Uveal Melanoma

NovelWise received FDA Orphan Drug Designation for NBM-BMX, its selective HDAC8 inhibitor for uveal melanoma, strengthening momentum after Fast Track status. SAN DIEGO, CA, UNITED STATES, November 24, 2025 /⁨EINPresswire.com⁩/ -- NovelWise Pharmaceutical …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on October 16, 2025 - 09:50 GMT

NovelWise Pharmaceutical Receives FDA Fast Track Designation for NBM-BMX in Metastatic Uveal Melanoma

Fast Track designation underscores NovelWise’s clinical momentum and the potential of NBM-BMX as a first-in-class HDAC8 inhibitor for metastatic uveal melanoma SAN DIEGO, CA, UNITED STATES, October 16, 2025 /⁨EINPresswire.com⁩/ -- Designation supported by …

Distribution channels: Healthcare & Pharmaceuticals Industry ...